Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: Systematic review and meta-analysis

Thorax

Volumn 66, Issue 5, 2011, Pages 383-388

  Singh, Sonal ^a   Loke, Yoon K ^b   Furberg, Curt D ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE REGISTRY; FOLLOW UP; HUMAN; INFECTION RISK; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 79954997496     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.152777     Document Type: Article

References (35)

1. Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol 2009;158:994-1003.
2. Matthews L, Berry A, Tersigni M, et al. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology 2009;150:75-86.
3. Spears M, Donnelly I, Jolly L, et al. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther 2009;86:49-53.
4. Narala VR, Ranga R, Smith MR, et al. Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma. Respir Res 2007;8:90.
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
6. Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35.
7. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. (Pubitemid 47403105)
8. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53. (Pubitemid 47219440)
9. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9.
10. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary diseaseda meta-analysis. Arch Intern Med 2009;169:219-29.
11. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
12. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206. (Pubitemid 47057766)
13. Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [Updated February 2008]. Chichester (UK): The Cochrane Collaboration, 2008. http://www.cochrane-handbook.org (accessed 15 Dec. 2010).
14. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77. (Pubitemid 46099417)
15. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
16. Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution 2005;59:464-8. (Pubitemid 40356057)
17. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. (Pubitemid 44903747)
18. GlaxoSmithKline Clinical Trials Register. A randomized, double-blind study to compare the durability of glucose lowering and preservation of pancreatic beta-cell function of rosiglitazone monotherapy compared to metformin or glyburide/glibenclamide in patients with drug-naive, recently diagnosed type 2 diabetes mellitus. Brentford (UK): GlaxoSmithKline 49653/048, 2007. http://www.gskclinicalstudyregister.com/files/pdf/20387.pdf (accessed 15 Dec. 2010).
19. Gerstein HC, Ratner RE, Cannon CP, et al; APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010;121:1176-87.
20. GlaxoSmithKline Clinical Trials Register. A phase III, 18 month, multicenter, randomized, double-blind, active-controlled clinical trial to compare rosiglitazone versus glipizide on the progression of atherosclerosis in subjects with type 2 diabetes mellitus and cardiovascular disease (APPROACH)/AVD 100521, 2010. Brentford (UK): Glaxo Smith Kline. http://www.gsk- clinicalstudyregister.com/files/pdf/20512.pdf (accessed 15 Dec. 2010).
21. GlaxoSmithKline Clinical Trials Register. A multicentre, double-blind, parallel group comparative study to evaluate the efficacy, safety and tolerability of rosiglitazone versus glibenclamide therapy, when administered to patients with type 2 diabetes mellitus. Brentford (UK): GlaxoSmithKline 49653/020, 2004. http://www.gsk-clinicalstudyregister.com/files/pdf/2834.pdf (accessed 15 Dec. 2010).
22. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007;49:1696-704. (Pubitemid 46589926)
23. Glaxo Smith Kline Clinical Trials Register. A 52-week double-blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes mellitus and congestive heart failure (NYHA class I/II). Brentford (UK): GlaxoSmithKline 49653/211, 2005. http://www.gsk- clinicalstudyregister.com/files/pdf/23019.pdf (accessed 15 Dec. 2010).
24. Hedblad B, Zambanini A, Nilsson P, et al. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007;261:293-305.
25. Glaxo Smith Kline Clinical Trials Register. Brentford (UK): GlaxoSmithKline. 49653/334. http://www.gsk-clinicalstudyregister.com/files/pdf/ 20391.pdf (accessed 15 Dec. 2010).
26. GlaxoSmithKline Clinical Trials Register. Rosiglitazone and plaque study: a 12 month randomised, double-blind, placebo controlled, magnetic resonance imaging study to evaluate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes mellitus and coexisting vascular disease or hypertension. Brentford (UK): GlaxoSmithKline, 49653/351, 2008. http://www.gsk-clinicalstudyregister.com/ files/pdf/23025.pdf (accessed 15 Dec. 2010).
27. Glaxo Smith Kline Clinical Trials Register. A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks' administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin [study no AVM100264]. Brentford (UK): GlaxoSmithKline AVM 100264, 2008. http://gsk-clinicalstudyregister.com/files/pdf/20518.pdf (accessed 15 Dec. 2010).
28. Rajagopalan R, Xu Y, Abbadessa M, et al; Quartet Study Group. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. Am J Geriatr Pharmacother 2006;4:123-33. (Pubitemid 44069474)
29. Schernthaner G, Matthews DR, Charbonnel B, et al; QUARTET Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76. (Pubitemid 39628416)
30. Charbonnel BH, Matthews DR, Schernthaner G, et al; QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405. (Pubitemid 40516237)
31. Hanefeld M, Brunetti P, Schernthaner GH, et al; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7. (Pubitemid 38196723)
32. Matthews DR, Charbonnel BH, Flanefeld M, et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74. (Pubitemid 40467663)
33. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003;26:510-13. (Pubitemid 36929083)
34. Hall JM, McDonnell DP. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 2007;21:1756-68. (Pubitemid 47173789)
35. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-99. (Pubitemid 351664540)